Flossbach Von Storch SE Makes New Investment in BioNTech SE Sponsored ADR $BNTX

Flossbach Von Storch SE acquired a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,226,138 shares of the company’s stock, valued at approximately $207,142,000. Flossbach Von Storch SE owned approximately 0.88% of BioNTech as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Larson Financial Group LLC increased its holdings in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the last quarter. EFG International AG acquired a new stake in BioNTech in the fourth quarter valued at $29,000. Caitong International Asset Management Co. Ltd grew its position in shares of BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after acquiring an additional 260 shares during the period. Tower Research Capital LLC TRC grew its position in shares of BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares during the period. Finally, Vestcor Inc acquired a new position in shares of BioNTech during the 4th quarter worth about $153,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

NASDAQ:BNTX opened at $113.12 on Thursday. The stock has a market cap of $28.61 billion, a P/E ratio of -14.45 and a beta of 1.27. The stock has a 50 day simple moving average of $92.48 and a 200 day simple moving average of $95.66. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $166.40 million during the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business’s revenue for the quarter was down 59.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.60) earnings per share. Research analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

BioNTech declared that its board has approved a share repurchase program on Thursday, May 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. UBS Group raised BioNTech from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $117.00 to $135.00 in a research report on Wednesday, May 27th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. Finally, Canaccord Genuity Group set a $142.00 price target on BioNTech in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BioNTech has an average rating of “Moderate Buy” and an average target price of $127.81.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.